RxDoctor Payments Data

Sonia Garg, MD

Advanced Heart Failure and Transplant Cardiology · Oakland, CANPI 1386873370

Payments from drug & device makers

$1,342in general payments, 2019–2025

Across 29 payments — averaging $46.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$472
  • Abbott$223
  • Impulse Dynamics (USA) Inc.$129
  • Bayer$113
  • United Therapeutics Corporation$107
  • Boston Scientific$82
  • plus $217 from 6 others

What the payments were for

  • Travel & lodging$23317%
  • Food & beverage$1,08981%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,342 in reported general payments places this provider in the 10th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$112,394
Medicare patients
264
Services billed
859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan42$50,268
Sirolimus42$36,152
JardianceEmpagliflozin41$32,946
EliquisApixaban41$31,145
Valganciclovir Hcl23$2,089
Eplerenone27$1,673
Cyclosporine ModifiedCyclosporine, Modified11$1,229
Metoprolol Succinate55$775
Tacrolimus16$761
Atorvastatin Calcium62$683
Isosorbide Dinitrate12$672
Losartan Potassium70$651
Bumetanide13$447
Carvedilol60$438
Rosuvastatin Calcium34$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$31,14541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →